期刊
NPJ VACCINES
卷 6, 期 1, 页码 -出版社
NATURE RESEARCH
DOI: 10.1038/s41541-021-00342-3
关键词
-
资金
- Merck Co.
- Texas Emerging Technology Fund
- Welch Foundation [AU-0042-20030616]
The study characterized 272 monoclonal antibodies isolated from memory B cells of individuals vaccinated with V160, revealing their specific binding to diverse HCMV antigens and potent neutralizing activity. It also found that V160 induced a specific class of antibodies, providing valuable insights into the primary targets for anti-HCMV antibodies induced by this vaccine.
A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-controlled phase I clinical trial (NCT01986010). However, the specificities and functional properties of V160-elicited antibodies remain undefined. Here, we characterized 272 monoclonal antibodies (mAbs) isolated from single memory B cells of six V160-vaccinated subjects. The mAbs bind to diverse HCMV antigens, including multiple components of the pentamer, gB, and tegument proteins. The most-potent neutralizing antibodies target the pentamer-UL subunits. The binding sites of the antibodies overlap with those of antibodies responding to natural HCMV infection. The majority of the neutralizing antibodies target the gHgL subunit. The non-neutralizing antibodies predominantly target the gB and pp65 proteins. Sequence analysis indicated that V160 induced a class of gHgL antibodies expressing the HV1-18/KV1-5 germline genes in multiple subjects. This study provides valuable insights into primary targets for anti-HCMV antibodies induced by V160 vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据